3933.HK
The United Laboratories International Holdings Limited [3933.HK] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
3933.HK Stock Summary
Top 10 Correlated ETFs
3933.HK
Top 10 Correlated Stocks
3933.HK
In the News
3933.HK Financial details
Company Rating
Strong Buy
Market Cap
17.66B
Income
3.23B
Revenue
23.23B
Book val./share
6.35
Cash/share
2.62
Dividend
0.2
Dividend %
2.61%
Employees
15K
Optionable
No
Shortable
Yes
Earnings
19 Mar 2024
P/E
7.94
Forward P/E
-
PEG
0.35
P/S
1.06
P/B
1.18
P/C
3.66
P/FCF
9.91
Quick Ratio
0.67
Current Ratio
1.78
Debt / Equity
0.13
LT Debt / Equity
0.08
-
-
EPS (TTM)
1.78
EPS next Y
-
EPS next Q
-
EPS this Y
61.11%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
18.65%
Revenue last 5Y
8.58%
Revenue Q/Q
12.26%
EPS Q/Q
36.54%
-
-
-
-
SMA20
11.11%
SMA50
42.86%
SMA100
25%
Inst Own
0.09%
Inst Trans
0%
ROA
8%
ROE
16%
ROC
0.18%
Gross Margin
44%
Oper. Margin
19%
Profit Margin
14%
Payout
17%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
5.6-10.24
52W High
-4.1%
52W Low
+91.8%
RSI
58
Rel Volume
0.53
Avg Volume
4.21M
Volume
2.23M
Perf Week
1.7%
Perf Month
12.56%
Perf Quarter
15.26%
Perf Half Y
9.47%
-
-
-
-
Beta
0.045
-
-
Volatility
0.12%, 0.49%
Prev Close
0.21%
Price
9.59
Change
-1.03%
3933.HK Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 4.09 | 5.12 | 4.97 | 5.27 | 6.23 | |
| Net income per share | 0.37 | 0.39 | 0.4 | 0.54 | 0.87 | |
| Operating cash flow per share | 0.66 | 1.1 | 0.89 | 0.84 | 1.12 | |
| Free cash flow per share | 0.38 | 0.84 | 0.59 | 0.58 | 0.69 | |
| Cash per share | 0.86 | 1.93 | 1.7 | 1.81 | 2.61 | |
| Book value per share | 3.34 | 4.07 | 4.88 | 5.08 | 5.83 | |
| Tangible book value per share | 3.33 | 4.06 | 4.87 | 5.07 | 5.83 | |
| Share holders equity per share | 3.34 | 4.07 | 4.88 | 5.08 | 5.83 | |
| Interest debt per share | 2.45 | 3.22 | 1.36 | 1.03 | 1.4 | |
| Market cap | 6.7B | 8.32B | 8.19B | 6.55B | 7.87B | |
| Enterprise value | 9.37B | 10.15B | 7.4B | 5.06B | 5.59B | |
| P/E ratio | 9.8 | 12.96 | 11.65 | 6.63 | 4.98 | |
| Price to sales ratio | 0.89 | 0.99 | 0.93 | 0.67 | 0.69 | |
| POCF ratio | 5.52 | 4.62 | 5.22 | 4.24 | 3.88 | |
| PFCF ratio | 9.54 | 6.07 | 7.9 | 6.17 | 6.29 | |
| P/B Ratio | 1.09 | 1.25 | 0.95 | 0.7 | 0.74 | |
| PTB ratio | 1.09 | 1.25 | 0.95 | 0.7 | 0.74 | |
| EV to sales | 1.25 | 1.21 | 0.84 | 0.52 | 0.49 | |
| Enterprise value over EBITDA | 5.73 | 6.3 | 4.05 | 2.56 | 2.2 | |
| EV to operating cash flow | 7.72 | 5.63 | 4.72 | 3.28 | 2.75 | |
| EV to free cash flow | 13.35 | 7.41 | 7.14 | 4.77 | 4.47 | |
| Earnings yield | 0.1 | 0.08 | 0.09 | 0.15 | 0.2 | |
| Free cash flow yield | 0.1 | 0.16 | 0.13 | 0.16 | 0.16 | |
| Debt to equity | 0.69 | 0.75 | 0.26 | 0.2 | 0.23 | |
| Debt to assets | 0.29 | 0.32 | 0.15 | 0.11 | 0.13 | |
| Net debt to EBITDA | 1.64 | 1.14 | -0.43 | -0.75 | -0.9 | |
| Current ratio | 1.03 | 1.35 | 1.69 | 1.53 | 1.78 | |
| Interest coverage | 3.66 | 3.63 | 6.79 | 22.94 | 24.7 | |
| Income quality | 1.78 | 2.81 | 2.23 | 1.56 | 1.28 | |
| Dividend Yield | 0.01 | 0.01 | 0.02 | 0.03 | 0.03 | |
| Payout ratio | 0.12 | 0.15 | 0.18 | 0.22 | 0.17 | |
| Sales general and administrative to revenue | 0.09 | 0.09 | 0.08 | 0.07 | 0.06 | |
| Research and developement to revenue | 0.04 | 0.05 | 0.04 | 0.05 | 0.05 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | -0.42 | -0.24 | -0.34 | -0.31 | -0.38 | |
| Capex to revenue | -0.07 | -0.05 | -0.06 | -0.05 | -0.07 | |
| Capex to depreciation | -0.7 | -0.65 | -0.88 | -0.79 | -1.46 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 5.29 | 5.99 | 6.61 | 7.83 | 10.68 | |
| ROIC | 0.07 | 0.07 | 0.09 | 0.1 | 0.12 | |
| Return on tangible assets | 0.05 | 0.04 | 0.05 | 0.06 | 0.08 | |
| Graham Net | -2.15 | -1.92 | -0.24 | -0.05 | 0.45 | |
| Working capital | 181.81M | 2.25B | 3.37B | 3.45B | 5.48B | |
| Tangible asset value | 6.11B | 6.66B | 8.6B | 9.33B | 10.6B | |
| Net current asset value | -1.78B | -314.38M | 1.87B | 3B | 4.14B | |
| Invested capital | 0.69 | 0.75 | 0.26 | 0.2 | 0.23 | |
| Average receivables | 2.63B | 2.77B | 2.76B | 3.19B | 3.95B | |
| Average payables | 2.06B | 2.28B | 2.28B | 2.74B | 3.38B | |
| Average inventory | 1.32B | 1.52B | 1.5B | 1.72B | 2.08B | |
| Days sales outstanding | 144.05 | 111.92 | 122.86 | 128.78 | 144.14 | |
| Days payables outstanding | 186.8 | 174.66 | 167.39 | 213.37 | 204.05 | |
| Days of inventory on hand | 119.91 | 120.5 | 104.99 | 133.18 | 124.07 | |
| Receivables turnover | 2.53 | 3.26 | 2.97 | 2.83 | 2.53 | |
| Payables turnover | 1.95 | 2.09 | 2.18 | 1.71 | 1.79 | |
| Inventory turnover | 3.04 | 3.03 | 3.48 | 2.74 | 2.94 | |
| ROE | 0.11 | 0.1 | 0.08 | 0.11 | 0.15 | |
| Capex per share | -0.28 | -0.26 | -0.3 | -0.26 | -0.43 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
| Metric | History | 2021-06-30 | 2021-12-31 | 2022-06-30 | 2022-12-31 | 2023-06-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 2.56 | 2.71 | 2.84 | 3.39 | 3.8 | |
| Net income per share | 0.34 | 0.2 | 0.35 | 0.52 | 0.71 | |
| Operating cash flow per share | 0.47 | 0.37 | 0.36 | 0.75 | 0.66 | |
| Free cash flow per share | 0.28 | 0.3 | 0.19 | 0.5 | 0.4 | |
| Cash per share | 1.97 | 1.81 | 2.22 | 2.61 | 2.62 | |
| Book value per share | 4.94 | 5.08 | 5.35 | 5.84 | 6.35 | |
| Tangible book value per share | 4.87 | 5.07 | 5.29 | 5.83 | 6.29 | |
| Share holders equity per share | 4.94 | 5.08 | 5.35 | 5.84 | 6.35 | |
| Interest debt per share | 1.22 | 1 | 1.17 | 1.35 | 0.84 | |
| Market cap | 9.76B | 6.55B | 7.23B | 7.86B | 10.98B | |
| Enterprise value | 8.48B | 5.06B | 5.34B | 5.58B | 7.77B | |
| P/E ratio | 3.92 | 4.48 | 2.87 | 2.07 | 2.14 | |
| Price to sales ratio | 2.07 | 1.31 | 1.4 | 1.28 | 1.59 | |
| POCF ratio | 11.27 | 9.68 | 10.96 | 5.74 | 9.17 | |
| PFCF ratio | 18.88 | 12.05 | 21.19 | 8.64 | 15.1 | |
| P/B Ratio | 1.07 | 0.7 | 0.74 | 0.74 | 0.95 | |
| PTB ratio | 1.07 | 0.7 | 0.74 | 0.74 | 0.95 | |
| EV to sales | 1.8 | 1.01 | 1.03 | 0.91 | 1.12 | |
| Enterprise value over EBITDA | 7.72 | 5.75 | 4.69 | 3.99 | 4.32 | |
| EV to operating cash flow | 9.79 | 7.48 | 8.1 | 4.07 | 6.48 | |
| EV to free cash flow | 16.41 | 9.31 | 15.65 | 6.14 | 10.67 | |
| Earnings yield | 0.06 | 0.06 | 0.09 | 0.12 | 0.12 | |
| Free cash flow yield | 0.05 | 0.08 | 0.05 | 0.12 | 0.07 | |
| Debt to equity | 0.25 | 0.2 | 0.22 | 0.23 | 0.13 | |
| Debt to assets | 0.14 | 0.11 | 0.12 | 0.13 | 0.08 | |
| Net debt to EBITDA | -1.16 | -1.69 | -1.66 | -1.63 | -1.79 | |
| Current ratio | 1.67 | 1.53 | 1.6 | 1.78 | 1.87 | |
| Interest coverage | 0 | 0 | 0 | 0 | 0 | |
| Income quality | 1.39 | 1.85 | 1.05 | 1.44 | 0.93 | |
| Dividend Yield | 0 | 0.03 | 0 | 0.03 | 0 | |
| Payout ratio | 0 | 0.61 | 0 | 0.29 | 0 | |
| Sales general and administrative to revenue | 0.07 | 0.07 | 0.07 | 0.06 | 0.06 | |
| Research and developement to revenue | 0.04 | 0.05 | 0.05 | 0.06 | 0.05 | |
| Intangibles to total assets | 0.01 | 0 | 0.01 | 0 | 0 | |
| Capex to operating cash flow | -0.4 | -0.2 | -0.48 | -0.34 | -0.39 | |
| Capex to revenue | -0.07 | -0.03 | -0.06 | -0.07 | -0.07 | |
| Capex to depreciation | -1.16 | -0.44 | -1.09 | -1.9 | -1.55 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 6.13 | 4.76 | 6.45 | 8.29 | 10.05 | |
| ROIC | 0.06 | 0.04 | 0.05 | 0.07 | 0.09 | |
| Return on tangible assets | 0.04 | 0.02 | 0.04 | 0.05 | 0.07 | |
| Graham Net | 0.02 | -0.05 | 0.21 | 0.45 | 0.77 | |
| Working capital | 3.76B | 3.45B | 4.11B | 5.48B | 6.15B | |
| Tangible asset value | 8.96B | 9.33B | 9.63B | 10.6B | 11.44B | |
| Net current asset value | 2.65B | 3B | 3.37B | 4.14B | 4.97B | |
| Invested capital | 0.25 | 0.2 | 0.22 | 0.23 | 0.13 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 59.49 | 61.82 | 65.64 | 65.47 | 65.59 | |
| Days payables outstanding | 89.16 | 100.71 | 93.71 | 93.17 | 96.33 | |
| Days of inventory on hand | 56.72 | 62.86 | 68.2 | 56.65 | 53.41 | |
| Receivables turnover | 1.51 | 1.46 | 1.37 | 1.37 | 1.37 | |
| Payables turnover | 1.01 | 0.89 | 0.96 | 0.97 | 0.93 | |
| Inventory turnover | 1.59 | 1.43 | 1.32 | 1.59 | 1.69 | |
| ROE | 0.07 | 0.04 | 0.06 | 0.09 | 0.11 | |
| Capex per share | -0.19 | -0.07 | -0.17 | -0.25 | -0.26 |
3933.HK Frequently Asked Questions
What is The United Laboratories International Holdings Limited stock symbol ?
The United Laboratories International Holdings Limited is a HK stock and trading under the symbol 3933.HK
What is The United Laboratories International Holdings Limited stock quote today ?
The United Laboratories International Holdings Limited stock price is $9.59 today.
Is The United Laboratories International Holdings Limited stock public?
Yes, The United Laboratories International Holdings Limited is a publicly traded company.
Company Profile
- Volume Average 4.21M
- Market Capitalization 17.66B
- Employee 15K
- CEO Mr. Hoi Shan Tsoi
- Headquarters Yuen Long,HK
- IPO Date 2007-06-15
-
Website
https://www.tul.com.cn 
The United Laboratories International Holdings Limited, an investment holding company, engages in the research, development, manufacture, distribution, and sale of pharmaceutical products. It operates through three segments: Bulk Medicine, Intermediate Products, and Finished Products. The company offers oral antibiotics, antimicrobials for injection, anti-cold products, cough medicines, ophthalmic drugs, antiviral drugs, anti-hepatitis B drugs, diabetes drugs, skin drugs for external use, cardiovascular and cerebrovascular drugs, nervous system drugs, vitamins, and vacant gelatin capsules, as well as API and intermediate products. It also manufactures and sells soft capsules casings; holds trademarks; and trades in pharmaceutical products. In addition, the company provides management services. It has operations in the People's Republic of China, Europe, India, the Middle East, South America, other Asian regions, and internationally. The company was founded in 1990 and is headquartered in Yuen Long, Hong Kong.
